The growing adoption of GLP-1 medications is reshaping the pharmaceutical and healthcare industries. Originally developed primarily for type 2 diabetes management, GLP-1 therapies have expanded into obesity and broader cardiometabolic care, creating significant opportunities for pharmaceutical companies, contract manufacturers, healthcare providers, and other industry stakeholders.
According to MarketsandMarkets, the global GLP-1 agonists market is projected to grow from USD 64.42 billion in 2025 to USD 170.75 billion by 2033, representing a CAGR of 13.0% during the forecast period.
This rapid expansion is creating a new competitive landscape across drug development, manufacturing, formulation technologies, supply chains, and healthcare delivery.
What Are GLP-1 Medications?
GLP-1 medications are therapies that target the glucagon-like peptide-1 pathway. They can help regulate blood glucose, influence appetite, and support weight management.
Key products and molecules in the evolving market include semaglutide, tirzepatide, dulaglutide, and emerging therapies such as oral GLP-1 candidates and next-generation combination treatments. MarketsandMarkets identifies products including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Trulicity, Orforglipron, CagriSema, and other emerging therapies within the market landscape.
For B2B stakeholders, the significance of these medications extends beyond clinical demand. Increasing adoption is generating opportunities throughout the pharmaceutical value chain.
Why Is Demand for GLP-1 Medications Increasing?
Several factors are contributing to the growth of the GLP-1 medications market.
Rising Prevalence of Diabetes and Obesity
The increasing global burden of type 2 diabetes and obesity is one of the primary demand drivers. As healthcare systems seek more effective approaches to metabolic disease management, demand for GLP-1 therapies continues to increase.
Expansion Into New Indications
GLP-1 therapies are increasingly being evaluated and adopted across broader cardiometabolic applications. This expansion can increase the addressable patient population and create additional commercial opportunities for pharmaceutical companies.
Growing Manufacturing Capacity
Manufacturing capacity is becoming a critical component of the GLP-1 ecosystem. Pharmaceutical companies and CDMOs are investing in facilities, technologies, APIs, and finished-dose manufacturing to respond to increasing demand.
Industry reports also indicate that Indian CDMOs are expanding capacity for peptide APIs, sterile fill-finish operations, injector devices, and glass cartridges as demand for GLP-1 therapies grows.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218746186
B2B Opportunities Across the GLP-1 Value Chain
The growth of GLP-1 medications creates opportunities well beyond innovative drug manufacturers.
Pharmaceutical Manufacturers
Drug manufacturers are investing in new molecules, formulations, delivery systems, and additional indications. The market is also attracting companies developing biosimilars and alternative formulations.
CDMOs and CMOs
Contract development and manufacturing organizations can benefit from demand for:
- Peptide API manufacturing
- Drug-product manufacturing
- Sterile fill-finish services
- Injectable formulations
- Oral formulations
- Device and cartridge manufacturing
- Analytical and quality-control services
The increasing complexity of GLP-1 production makes specialized manufacturing capabilities particularly valuable.
API Suppliers
As GLP-1 therapies scale globally, reliable access to high-quality APIs is becoming strategically important. Suppliers with appropriate peptide manufacturing capabilities, regulatory compliance, and scalable production can become important partners for pharmaceutical companies.
Drug-Delivery Companies
The transition toward more convenient delivery formats is creating opportunities for companies involved in injectors, pens, cartridges, and oral drug-delivery technologies.
MarketsandMarkets identifies single-dose, multi-dose, and tablet formats, with single-dose products holding the largest share in its analysis.
Healthcare and Weight-Management Providers
The commercial ecosystem is also expanding beyond traditional pharmaceutical channels. Weight-management centers, fitness businesses, nutrition companies, clinics, and home-care settings are increasingly interacting with patients using GLP-1 therapies.
Oral GLP-1 Medications Could Reshape the Market
One of the most important developments for pharmaceutical businesses is the advancement of oral GLP-1 medications.
Oral formulations could address some of the barriers associated with injectable therapies and potentially improve convenience and patient acceptance. MarketsandMarkets identifies increasing research into oral GLP-1 therapies as a significant market opportunity.
For manufacturers and technology providers, this creates potential demand for new formulation technologies, oral delivery platforms, manufacturing processes, and specialized packaging.
The Role of Biosimilars and Generic Competition
The GLP-1 market is also entering a period of increased competitive activity as patent expirations create opportunities for biosimilar and generic development in applicable markets.
This could change the competitive structure of the industry by expanding access while increasing pressure on pricing, manufacturing efficiency, quality, and supply-chain capabilities.
For B2B pharmaceutical companies, the ability to produce high-quality products at competitive costs could become increasingly important.
Key Challenges for the GLP-1 Industry
Despite strong growth prospects, companies operating in the GLP-1 ecosystem face several challenges.
Manufacturing capacity: Rapid demand growth can place pressure on peptide API and finished-dose manufacturing capacity.
Regulatory requirements: GLP-1 products require rigorous quality, safety, manufacturing, and regulatory compliance.
Cost and payer pressure: High treatment costs and evolving reimbursement policies can influence market access. MarketsandMarkets identifies stringent cost and payer controls as a significant market restraint.
Supply-chain complexity: Injectable products require specialized manufacturing, sterile processing, devices, packaging, and distribution capabilities.
Counterfeit and unauthorized products: The growth of unauthorized and counterfeit GLP-1 products presents regulatory, safety, and brand-protection challenges.
What Does the Future Hold for GLP-1 Medications?
The future of GLP-1 medications is likely to be shaped by three major developments: new indications, improved formulations, and greater manufacturing capacity.
The industry is moving beyond traditional diabetes treatment toward a broader metabolic-health platform. Emerging oral therapies, combination treatments, biosimilars, and next-generation molecules could further diversify the market.
For B2B organizations, this evolution creates opportunities to participate at multiple points—from API production and drug development to CDMO services, delivery technologies, packaging, logistics, and healthcare support services.
The broader industry outlook is also supported by recent research highlighting opportunities for innovation, contract manufacturing, and generic pharmaceutical companies as GLP-1 therapies expand.